Applications

1705 – Structured prenatal risk assessment for preterm preeclampsia

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation Closed
  • Pre-MSAC consultation Closed
  • Outcome Not supported

Application details

Reason for application

New MBS item.

Service or technology in this application

Pre-term preeclampsia risk assessment performed using a multi-variate testing algorithm at 11-13+6 weeks’ gestation. The algorithm includes:

  • Clinical measurement of maternal Mean Arterial Pressure
  • Biochemical measurement of maternal serum concentration of Placental Growth Factor; and
  • Ultrasound assessment of uterine perfusion (Doppler measurement of uterine artery pulsatility index).

Type: Investigative medical technology

Medical condition this application addresses

Preeclampsia is a pregnancy-specific condition resulting in maternal hypertension (high blood pressure) and multisystem dysfunction. Once preeclampsia develops, it becomes progressively worse until infant delivery.

Preterm preeclampsia is a more severe form of disease with earlier onset that causes more cardiovascular morbidity for mothers in later life. The preeclamptic fetus is often growth restricted. Planned pre-term birth puts the surviving fetus at substantially increased risk of death or lifelong morbidity.

Consultation survey and deadlines

  • PASC consultation: Closed
  • MSAC consultation: Closed Friday 6 October 2023

Meetings to consider this application

  • PASC meeting: 13–14 April 2022
  • ESC meeting: 5–6 October 2023
  • MSAC meeting: 23–24 November 2023